Voleon Capital Management LP Makes New $1.65 Million Investment in Bruker Corporation $BRKR

Key Points

• Voleon Capital Management LP acquired 39,624 shares of Bruker Corporation, valued at approximately $1,654,000, during the first quarter of the year.
• Bruker Corporation reported a quarterly earnings miss, with earnings per share of $0.32, falling short of the consensus estimate of $0.33.
• The company declared a $0.05 quarterly dividend to be paid on October 3rd, representing an annualized dividend yield of 0.6%.

Voleon Capital Management LP acquired a new stake in Bruker Corporation (NASDAQ:BRKR - Free Report) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 39,624 shares of the medical research company's stock, valued at approximately $1,654,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in BRKR. London Co. of Virginia raised its holdings in shares of Bruker by 78.4% in the fourth quarter. London Co. of Virginia now owns 4,193,454 shares of the medical research company's stock valued at $245,820,000 after purchasing an additional 1,843,294 shares during the last quarter. Sculptor Capital LP raised its holdings in shares of Bruker by 484.1% in the fourth quarter. Sculptor Capital LP now owns 1,714,015 shares of the medical research company's stock valued at $100,476,000 after purchasing an additional 1,420,569 shares during the last quarter. Steadfast Capital Management LP acquired a new stake in shares of Bruker in the fourth quarter valued at approximately $63,997,000. Goldman Sachs Group Inc. raised its holdings in shares of Bruker by 107.3% in the first quarter. Goldman Sachs Group Inc. now owns 1,465,319 shares of the medical research company's stock valued at $61,162,000 after purchasing an additional 758,301 shares during the last quarter. Finally, AQR Capital Management LLC raised its holdings in shares of Bruker by 65.9% in the first quarter. AQR Capital Management LLC now owns 1,476,605 shares of the medical research company's stock valued at $60,688,000 after purchasing an additional 586,516 shares during the last quarter. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director Cynthia M. Friend sold 3,535 shares of the company's stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $32.25, for a total transaction of $114,003.75. Following the completion of the sale, the director owned 18,016 shares of the company's stock, valued at $581,016. This represents a 16.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 27.30% of the stock is owned by corporate insiders.

Bruker Price Performance

BRKR traded down $1.16 on Friday, hitting $30.91. 2,838,988 shares of the stock were exchanged, compared to its average volume of 2,675,270. Bruker Corporation has a 12 month low of $28.53 and a 12 month high of $72.94. The business has a 50-day moving average of $36.25 and a two-hundred day moving average of $39.11. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.61 and a quick ratio of 0.70. The firm has a market capitalization of $4.69 billion, a price-to-earnings ratio of 59.44, a PEG ratio of 4.23 and a beta of 1.21.

Bruker (NASDAQ:BRKR - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The medical research company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.01). Bruker had a return on equity of 17.89% and a net margin of 2.31%.The firm had revenue of $797.40 million for the quarter, compared to the consensus estimate of $811.17 million. During the same period in the prior year, the company earned $0.52 EPS. The company's revenue for the quarter was down .4% compared to the same quarter last year. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. Sell-side analysts forecast that Bruker Corporation will post 2.69 EPS for the current fiscal year.

Bruker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 3rd. Investors of record on Tuesday, September 23rd will be given a dividend of $0.05 per share. The ex-dividend date of this dividend is Tuesday, September 23rd. This represents a $0.20 annualized dividend and a yield of 0.6%. Bruker's dividend payout ratio is currently 38.46%.

Analysts Set New Price Targets

BRKR has been the topic of a number of recent research reports. Barclays lowered their price objective on shares of Bruker from $46.00 to $43.00 and set an "overweight" rating on the stock in a report on Monday, August 4th. Citigroup lowered their target price on shares of Bruker from $40.00 to $38.00 and set a "neutral" rating on the stock in a report on Monday, August 4th. Jefferies Financial Group set a $60.00 target price on shares of Bruker and gave the stock a "buy" rating in a report on Monday, August 4th. Bank of America lowered their target price on shares of Bruker from $61.00 to $50.00 and set a "buy" rating on the stock in a report on Thursday, June 26th. Finally, Wells Fargo & Company decreased their price objective on shares of Bruker from $60.00 to $50.00 and set an "overweight" rating on the stock in a report on Tuesday, August 5th. Five investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, Bruker has a consensus rating of "Hold" and an average price target of $51.30.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.